DANYELZA 40 mg/10mL
Naxitamab · INJECTION · Y-mAbs Therapeutics, Inc.
No Recall History
Plain English
DANYELZA is a injection containing naxitamab at 40 mg/10mL, taken intravenous. Manufactured by Y-mAbs Therapeutics, Inc..
Key Facts
- Brand Name
- DANYELZA
- Generic Name
- Naxitamab
- NDC Code (Product)
73042-201- Manufacturer
- Y-mAbs Therapeutics, Inc.
- Strength
- 40 mg/10mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761171
- Drug Class
- Glycolipid Disialoganglioside-directed Antibody [EPC]
- Marketing Start
- 11/25/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is DANYELZA used for?
DANYELZA contains Naxitamab. It is a injection taken intravenous. Consult your doctor for specific uses.
Is DANYELZA a controlled substance?
DANYELZA is not classified as a controlled substance by the DEA.
What is the generic name for DANYELZA?
The generic name for DANYELZA is Naxitamab. There are no other listed brand versions of Naxitamab.
What is the NDC code for DANYELZA 40 mg/10mL?
The NDC (National Drug Code) for DANYELZA 40 mg/10mL is 73042-201, listed by Y-mAbs Therapeutics, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)